MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company develops MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent in Phase 2b/3 clinical trial for treating neurological and other disorders, such as progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID. It is also developing MN-001 (tipelukast), an orally bioavailable small molecule compound in Phase 2 clinical trial to treat fibrotic and other metabolic disorders, including nonalcoholic fatty liver disease and hypertriglycedemia. The company has a license agreement with Kyorin Pharmaceuticals for the development and commercialization of MN-166 and MN-001. MediciNova, Inc. was incorporated in 2000 and is headquartered in La Jolla, California. Show more

Location: 4275 Executive Square, La Jolla, CA, 92037, United States | Website: https://medicinova.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

62.29M

52 Wk Range

$1.12 - $2.55

Previous Close

$1.27

Open

$1.26

Volume

10,529

Day Range

$1.26 - $1.32

Enterprise Value

28.03M

Cash

36.57M

Avg Qtr Burn

-2.64M

Insider Ownership

2.98%

Institutional Own.

21.88%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
MN-166 (ibudilast) Details
Neurological disorder, Degenerative Cervical Myelopathy

Phase 2/3

Data readout

MN-166 (ibudilast) Details
Amyotrophic lateral sclerosis, Neurodegenerative disease

Phase 2/3

Data readout

MN-166 (ibudilast) Details
Neuropathy, Neurological disorder

Phase 2b

Data readout

MN-166 (ibudilast) Details
Alcohol dependence

Phase 2b

Update

MN-001 (tipelukast) Details
Liver disease, Non-alcoholic steatohepatitis

Phase 2

Interim update

MN-166 (ibudilast) Details
Glioblastoma, Cancer

Phase 2

Update

Phase 2

Update

MN-001 (tipelukast) Details
Interstitial lung disease, Lung disease, Idiopathic pulmonary fibrosis

Phase 2

Update

MN-166 (ibudilast) Details
Multiple sclerosis, Central nervous system illness

Phase 2

Update

SAR444836 Details
Phenylketonuria

Phase 1/2

Data readout